Retraction notice to “Paraoxonase I polymorphisms and attention/hyperactivity in school-age children from Mexico City, Mexico” Environmental Research (2014) 342 -349 (RETRACTED: Paraoxonase I polymorphisms and attention/hyperactivity in school-age children from Mexico City, Mexico (2014) 132 (342–349), (S0013935114001005) (10.1016/j.envres.2014.04.010));Paraoxonase I polymorphisms and attention/hyperactivity in school-age children from Mexico City, Mexico

Environmental Research

Volumn 132, Issue , 2014, Pages 342-349

  Fortenberry, Gamola Z ^a   Meeker, John D ^a   Sánchez, Brisa N ^a   Bellinger, David ^b   Peterson, Karen ^a   Schnaas, Lourdes ^c   Solano González, Maritsa ^d   Ettinger, Adrienne S ^a,b,e   Hernandez Avila, Mauricio ^d   Hu, Howard ^f   Maria Tellez Rojo, Martha ^d  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^e YALE UNIVERSITY   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

ADHD; Biomarker; Exposure; Human; Paraoxonase 1 polymorphisms

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; DNA; ORGANOPHOSPHATE;

BIOMARKER; CHILD HEALTH; ENZYME ACTIVITY; GENOTYPE; HEALTH RISK; MATERNAL HEALTH; ORGANOPHOSPHATE; POLLUTION EXPOSURE; POLYMORPHISM;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR ASSESSMENT SYSTEM FOR CHILDREN 2; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CONNER PARENT RATING SCALES REVISED; CONTINUOUS PERFORMANCE TEST; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRENATAL EXPOSURE; PRIORITY JOURNAL; SCHOOL CHILD;

FEDERAL DISTRICT [MEXICO]; MEXICO CITY; MEXICO [NORTH AMERICA];

ADHD; BIOMARKER; EXPOSURE; HUMAN; PARAOXONASE 1 POLYMORPHISMS;

ADULT; ARYLDIALKYLPHOSPHATASE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEXICO; ORGANOPHOSPHATES; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84900385682     PISSN: 00139351     EISSN: 10960953     Source Type: Journal    
DOI: 10.1016/j.envres.2018.06.050     Document Type: Erratum

References (54)

1. American Psychiatric Association, 4th ed., text rev. 2000. Diagnostic and statisticalmanual of mental disorders. Washington, DC.
2. Androutsopoulos V.P., Kanavouras K., Tsatsakis A.M. Role of paraoxonase 1 (PON1) in organophosphate metabolism: Implications in neurodegenerative diseases. Toxicol. Appl. Pharmacol. 2011, 256(3):418-424. 10.1016/j.taap.2011.08.009.
3. Berkowitz G.S., Wetmur J.G., Birman-Deych E., Obel J., Lapinski R.H., Godbold J.H., Wolff M.S. In utero pesticide exposure, maternal paraoxonase activity, and head circumference. Environ. Health Perspect. 2004, 112(3):388-391.
4. Boyle C.A., Boulet S., Schieve L.A., Cohen R.A., Blumberg S.J., Yeargin-Allsopp M., Visser S., Kogan M.D. Trends in the prevalence of developmental disabilities in US children, 1997-2008. Pediatrics 2011, 127(6):1034-1042.
5. Bouchard M.F., Bellinger D.C., Wright R.O., Weisskopf M.G. Attention-deficit/hyperactivity disorder and urinary metabolites of organophosphate pesticides. Pediatrics 2010, 125(6):e1270-e1277. (10.1542/peds.2009-3058). 10.1542/peds.2009-3058.
6. Bradman A., Whyatt R. Characterizing exposures to nonpersistent pesticides during pregnancy and early childhood in the national children[U+05F3]s study: a review of monitoring and measurement methodologies. Environ. Health Perspect. 2005, 113(8):1092-1099.
7. Braun J.M., Hoffman E., Schwartz J., Sanchez B., Schnaas L., Mercado-Garcia A., Hernandez-Avila M. Assessing windows of susceptibility to lead-induced cognitive deficits in mexican children. Neurotoxicology 2012, 33(5):1040-1047. 10.1016/j.neuro.2012.04.022.
8. Brophy V.H., Hastings M.D., Clendenning J.B., Richter R.J., Jarvik G.P., Furlong C.E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001, 11(1):77-84.
9. CDC, 2012. (accessed 10.09.2012). http://www.cdc.gov/biomonitoring/Chlorpyrifos_BiomonitoringSummary.html.
10. CDC, 2011. (accessed 24.11.2012). http://www.cdc.gov/ncbddd/adhd/data.html.
11. Ceylan M.F., Sener S., Bayraktar A.C., Kavutcu M. Changes in oxidative stress and cellular immunity serum markers in attention-deficit/hyperactivity disorder. Psychiatry Clin. Neurosci. 2012, 66(3):220-226. 10.1111/j.1440-1819.2012.02330.x.
12. Chen J., Kumar M., Chan W., Berkowitz G., Wetmur J.G. Increased influence of genetic variation on PON1 activity in neonates. Environ. Health Perspect. 2003, 111(11):1403-1409.
13. Cole T., Walter B., Shih D., Tward A., Lusis A., Timchalk C., Furlong C. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogen. Genomics 2005, 15(8):589-598.
14. Conners C.K., Staff M. Conners[U+05F3] Continuous Performance Test II (CPT II) Computer Program for Windows 2000, Psychological Assessment Resources, Odessa (FL).
15. Conners C. K. 1989. Conners'Rating Scale Manual. Multi-Health Systems Inc., New York.
16. Conner Profile. (accessed 20.10.2012). http://www.damianbariexca.net/wp-content/docs/Conners%20ADHD%20Report.pdf.
17. Costa L.G., Cole T.B., Jarvik G.P., Furlong C.E. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu. Rev. Med. 2003, 54:371-392. 10.1146/annurev.med.54.101601.152421.
18. Costa L.G., Cole T.B., Vitalone A., Furlong C.E. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin. Chim. Acta 2005, 352(1-2):37-47. 10.1016/j.cccn.2004.09.019.
19. Deaton A., Grosh M. Consumption. Designing household survey questionnaires for developing countries: Lessons from 15 years of the living standards measurement study 2000, 91-133. Oxford University Press, Oxford. M. Grosh, P. Glewee (Eds.).
20. Deb S., Dhaliwal A.J., Roy M. The usefulness of conners[U+05F3] rating scales-revised in screening for attention deficit hyperactivity disorder in children with intellectual disabilities and borderline intelligence. J. Intellect. Disabil. Res.: JIDR 2008, 52(11):950-965. 10.1111/j.1365-2788.2007.01035.x.
21. Eaton D., Daroff R., Autrup H., Bridges J., Buffler P., Costa L., Spencer P. Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment. Crit. Rev. Toxicol. 2008, 38(Suppl. 2):S1-S125.
22. Engel S.M., Wetmur J., Chen J., Zhu C., Barr D.B., Canfield R.L., Wolff M.S. Prenatal exposure to organophosphates, paraoxonase 1, and cognitive development in childhood. Environ. Health Perspect. 2011, 119:8.
23. Eskenazi B., Huen K., Marks A., Harley K.G., Bradman A., Barr D.B., Holland N. PON1 and neurodevelopment in children from the CHAMACOS study exposed to organophosphate pesticides in utero. Environ. Health Perspect. 2010, 118(12):1775-1781. 10.1289/ehp.1002234.
24. Eskenazi B., Marks A., Bradman A., Harley K., Barr D., Johnson C., Jewell N. Organophosphate pesticide exposure and neurodevelopment in young mexican-american children. Environ. Health Perspect. 2007, 115(5):792-798.
25. Eskenazi B., Bradman A., Castorina R. Exposures of children to organophosphate pesticides and their potential adverse health effects. Environ. Health Perspect. 1999, 107(Suppl 3):S409-S419. (1999).
26. Essawy H., El-Ghohary I., El-Missiry A., Kahla O., Soliman A., El-Rashidi O. Oxidative stress in attention deficit hyperactivity disorder patients. Curr. Psychiatry [Egypt] 2009, 16:1.
27. Ettinger A.S., Lamadrid-Figueroa H., Tellez-Rojo M.M., Mercado-Garcia A., Peterson K.E., Schwartz J., Hernandez-Avila M. Effect of calcium supplementation on blood lead levels in pregnancy: a randomized placebo-controlled trial. Environ. Health Perspect. 2009, 117(1):26-31. 10.1289/ehp.11868.
28. Furlong C.E., Cole T.B., Jarvik G.P., Pettan-Brewer C., Geiss G.K., Richter R.J., Costa L.G. Role of paraoxonase (PON1) status in pesticide sensitivity: Genetic and temporal determinants. Neurotoxicology 2005, 26(4):651-659. 10.1016/j.neuro.2004.08.002.
29. Furlong C., Holland N., Richter R., Bradman A., Ho A., Eskenazi B. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogen. Genomics 2006, 16(3):183-190.
30. Gabriel, S., Ziaugra, L., Tabbaa, D. 2009. SNP genotyping using the sequenom MassARRAY iPLEX platform. Current Protocols in Human Genetics/Editorial Board, Jonathan L.Haines. [Et Al.], Chapter 2, Unit 2.12. 10.1002/0471142905.hg0212s60. http://dx.doi.org/10.1002/0471142905.hg0212s60.
31. Harley K.G., Huen K., Schall R.A., Holland N.T., Bradman A., Barr D.B., Eskenazi B. Association of organophosphate pesticide exposure and paraoxonase with birth outcome in mexican-american women. PloS One 2011, 6(8):e23923. 10.1371/journal.pone.0023923.
32. Hernandez-Avila M., Gonzalez-Cossio T., Hernandez-Avila J.E., Romieu 578 I., Peterson K.E., Aro A., et al. Dietary calcium supplements 579 to lower blood lead levels in lactating women: a randomized 580 placebocontrolled trial. Epidemiology (Cambridge, Mass.) 2003, 14(2). (206-212). http://dx.doi.org/10.1097/01.ED.E.0000038520.66094.34.
33. Hernandez A.F., Lacasana M., Gil F., Rodriguez-Barranco M., Pla A., Lopez-Guarnido O. Evaluation of pesticide-induced oxidative stress from a gene-environment interaction perspective. Toxicology 2012, 307:95-102.
34. Holland N., Furlong C., Bastaki M., Richter R., Bradman A., Huen K., Eskenazi B. Paraoxonase polymorphisms, haplotypes, and enzyme activity in latino mothers and newborns. Environ. Health Perspect. 2006, 114(7):985-991.
35. Hu H., Tellez-Rojo M.M., Bellinger D., Smith D., Ettinger A.S., Lamadrid-Figueroa H., Hernandez-Avila M. Fetal lead exposure at each stage of pregnancy as a predictor of infant mental development. Environ. Health Perspect. 2006, 114(11):1730-1735.
36. Kawatani M., Tsukahara H., Mayumi M. Evaluation of oxidative stress status in children with pervasive developmental disorder and attention deficit hyperactivity disorder using urinary-specific biomarkers. Redox Report: Commun. Free Radical Res. 2011, 16(1):45-46. (10.1179/174329211×12968219310873). 10.1179/174329211×12968219310873.
37. Kotani K., Tsuzaki K., Sakane N. Paraoxonase-1 gene Q192R polymorphism and reactive oxygen metabolites. J. Int. Med. Res. 2012, 40(4):1513-1518.
38. Landrigan P.J., Claudio L., Markowitz S.B., Berkowitz G.S., Brenner B.L., Romero H., Wolff M.S. Pesticides and inner-city children: Exposures, risks, and prevention. Environ. Health Perspect. 1999, 107(Suppl 3):S431-S437.
39. Leviev, I., Negro, F., James, R.W. Two Alleles of the Human Paraoxonase Gene Produce Different Amounts of mRNA: An Explanation for Differences in Serum Concentrations of Paraoxonase Associated With the (Leu-Met54) Polymorphism. Arteriosclerosis, Thrombosis, and Vascular Biology. 17(11), 1997, 2935-2939.
40. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., Furlong C.E. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000, 10(9):767-779.
41. Li W.F., Pan M.H., Chung M.C., Ho C.K., Chuang H.Y. Lead Exposure Is Associated with Decreased Serum Paraoxonase 1 (PON1) Activity and Genotypes. Environmental Health Perspectives 2006, 114(8):1233-1236.
42. Marks A.R., Harley K., Bradman A., Kogut K., Barr D.B., Johnson C., Eskenazi B. Organophosphate pesticide exposure and attention in young mexican-american children: the CHAMACOS study. Environ. Health Perspect. 2010, 118(12):1768-1774. 10.1289/ehp.1002056.
43. Meyer B.D., Sullivan J.X. Measuring the well-being of the poor using income and consumption. J. Hum. Resour. 2003, v38(Suppl):S1180-S1220.
44. Oztop D., Altun H., Baskol G., Ozsoy S. Oxidative stress in children with attention deficit hyperactivity disorder. Clin. Biochem. 2012, 45(10-11):745-748. 10.1016/j.clinbiochem.2012.03.027.
45. Pearson Assessments. Pid=PAa30000 (accessed October 2012). http://www.pearsonassessments.com/HAIWEB/Cultures/en-us/Productdetail.htm?
46. Prakongsai, P, 2006. An Application of the Asset Index for Measuring Household Living Standards in Thailand.
47. Reynolds C.R., Kamphaus R.W. Behavior Assessment System for Children-Second Edition 1992, AGS Publishing.
48. Rojas-Garcia A.E., Solis-Heredia B., Pina-Guzman L., Vega L., Lopez-Carrillo B., Quintanilla-Vega B. Genetic polymorphisms and activity of PON1 in a Mexican population. Toxicology and Applied Pharmacology 2005, 205:282-289.
49. Stefanovic A., Ardalic D., Kotur-Stevuljevic J., Vujovic A., Spasic S., Spasojevic-Kalimanovska V., Cerovic N. Longitudinal changes in PON1 activities, PON1 phenotype distribution and oxidative status throughout normal pregnancy. Reprod. Toxicol. 2012, 33(1):20-26. (10.1016/j.reprotox.2011.10.009). 10.1016/j.reprotox.2011.10.009.
50. Stevenson D.E., Kehrer J.P., Kolaja K.L., Walborg E.F., Klaunig J.E. Effect of dietary antioxidants on dieldrin-induced hepato-toxicity in mice. Toxicol. Lett. 1995, 75:177-183.
51. Téllez-Rojo M.M., Hernández-Avila M., Lamadrid-Figueroa H., Smith D., Hernández-Cadena L., Mercado A., Hu H. Impact of bone lead and bone resorption on plasma and whole blood lead levels during pregnancy. Am. J. Epidemiol. 2004, 160(7):668-678. 10.1093/aje/kwh271.
52. Timchalk C., Busby A., Campbell J., Needham L., Barr D. Comparative pharmacokinetics of the organophosphorus insecticide chlorpyrifos and its major metabolites diethylphosphate, diethylthiophosphate and 3,5,6-trichloro-2-pyridinol in the rat. Toxicology 2007, 237(1-3):145.
53. Wechsler H. Wechsler Adult Intelligence Scale (WAIS), Spanish Version 1968, Psychological Corporation, San Antonio, TX.
54. Ye X., Pierik F., Hauser R., Duty S., Angerer J., Park M., Longnecker M. Urinary metabolite concentrations of organophosphorous pesticides, bisphenol A, and phthalates among pregnant women in Rotterdam, The Netherlands: the generation R study. Environ. Res. 2008, 108(2):260-267.